Sohal Aalam, Casanova Luis, Kowdley Kris V
Department of Hepatology, Liver Institute Northwest, Seattle, WA.
Department of Gastroenterology and Hepatology, Elson Floyd College of Medicine, Spokane, WA.
ACG Case Rep J. 2024 Oct 4;11(10):e01484. doi: 10.14309/crj.0000000000001484. eCollection 2024 Oct.
Tirzepatide is the first dual incretin glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor activator approved for the management of type II diabetes mellitus. This drug was also recently approved by the Food and Drug Administration as a management option for patients with obesity. Tirzepatide has been also reported to be beneficial in reducing liver fat content. Although its efficacy is well described in the literature, no cases of tirzepatide-induced hepatotoxicity have been reported. We report a case of a 37-year-old woman with metabolic syndrome who was noted to have elevated liver enzymes secondary to tirzepatide use.
替尔泊肽是首个被批准用于治疗2型糖尿病的双重肠促胰岛素——葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1受体激动剂。该药物最近也被美国食品药品监督管理局批准作为肥胖患者的一种治疗选择。据报道，替尔泊肽在降低肝脏脂肪含量方面也有好处。尽管其疗效在文献中有充分描述，但尚未有替尔泊肽引起肝毒性的病例报告。我们报告一例37岁患有代谢综合征的女性，因使用替尔泊肽导致肝酶升高。
